Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Pharmacokinetics of 6-mercaptopurine in patients with inflammatory bowel disease: implications for therapy.

Therapeutic drug monitoring - 1 Jun 2004

Derijks Luc J J, Gilissen Lennard P L, Engels Leopold G J B, Bos Laurens P, Bus Paul J, Lohman Joseph J H M, Curvers Wouter L, Van Deventer Sander J H, Hommes Daniel W, Hooymans Piet M

Abstract excerpt

Proper prospective pharmacokinetic studies of 6-mercaptopurine (6-MP) in inflammatory bowel disease (IBD) patients are lacking. As a result, conflicting recommendations have been made for metabolite monitoring in routine practice. The authors have evaluated 6-MP pharmacokinetics in IBD patients, including the genetic background for thiopurine methyltransferase (TPMT). Red blood cell (RBC) 6-thioguanine nucleotide...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Drug Monitoring
Share to Guanine Nucleotides

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Half-Life

Share to Immunosuppressive Agents

Share to Inflammatory Bowel Diseases

Share to Mercaptopurine

Share to Methyltransferases

Share to Thionucleotides

Source

Identifiers

PMID: 15167634
DOI: 10.1097/00007691-200406000-00016

Genes

TPMT

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Pharmacokinetics of 6-mercaptopurine in patients with inflammatory bowel disease: implications for therapy.PMID 15167634Read ↗

Pharmacogenomics and metabolite measurement for 6-mercaptopurine therapy in inflammatory bowel disease.Semantic proximity Read ↗

Azathioprine and 6‐mercaptopurine pharmacogenetics and metabolite monitoring in inflammatory bowel diseaseSemantic proximity Read ↗

Relationship Between Thiopurine S-Methyltransferase Genotype/Phenotype and 6-Thioguanine Nucleotide Levels in 316 Patients With Inflammatory Bowel Disease on 6-Thioguanine.Semantic proximity Read ↗

Clinical use and practical application of TPMT enzyme and 6-mercaptopurine metabolite monitoring in IBD.Semantic proximity Read ↗

Thiopurines in inflammatory bowel disease: pharmacogenetics, therapeutic drug monitoring and clinical recommendations.Semantic proximity Read ↗

Population pharmacokinetics of azathioprine active metabolite in patients with inflammatory bowel disease and dosage regimens optimisation.Semantic proximity Read ↗

Usefulness of thiopurine methyltransferase and thiopurine metabolite analysis in clinical practice in patients with inflammatory bowel diseases.Semantic proximity Read ↗

Deletion of glutathione-s-transferase m1 reduces azathioprine metabolite concentrations in young patients with inflammatory bowel disease.Semantic proximity Read ↗

A prospective evaluation of the impact of allopurinol in pediatric and adult IBD patients with preferential metabolism of 6-mercaptopurine to 6-methylmercaptopurine.Semantic proximity Read ↗

Review article: thiopurines in inflammatory bowel disease.Semantic proximity Read ↗

Early prediction of thiopurine-induced hepatotoxicity in inflammatory bowel disease.Semantic proximity Read ↗

The glutathione transferase Mu null genotype leads to lower 6-MMPR levels in patients treated with azathioprine but not with mercaptopurine.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.